Phase 2 Parkinson's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person must be able to give informed consent and follow the study procedures.
- The person must have been on a stable dose of Levodopa and/or dopamine-boosting medications for at least 4 weeks before joining the study.
- The person must have a clinical diagnosis of Parkinson's disease (PD), or Parkinson's disease with dementia, confirmed using recognised medical diagnostic guidelines.
- The person must score 18 or higher on the MoCA, which is a standard memory and thinking test.
- The person must be at a mid-range stage of Parkinson's disease, classified as Hoehn and Yahr stage 2 or 3 (confirm with trial site for what this means in practice).
- The person must be between 55 and 85 years old and in a generally stable state of health.
- The person must be fluent in English.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a known gene mutation linked to Parkinson's disease, such as PINK-1, DJ-1, parkin, or LRRK2.
- People who show signs of a brain or nervous system condition other than Parkinson's disease, such as Alzheimer's disease, multiple system atrophy, or other related disorders, or who have a history of stroke, head injury, or brain infection.
- People who have a psychiatric diagnosis or symptoms — such as hallucinations, suicidal thoughts, major depression, or delusions — that could interfere with study procedures.
- People with a medical history of liver, pancreatic, gastrointestinal, kidney, or blood disorders, or any other significant medical condition that is not well controlled and could affect safety or the study results.
- People who are currently active participants in another clinical trial.
- People who take blood-thinning medications, such as Coumadin, heparin, enoxaparin, or fondaparinux.
- People who have an immune system condition that is not well controlled, or that requires treatment with immunoglobulins, monoclonal antibodies, immunosuppressant medications, or a blood-filtering procedure called plasmapheresis (confirm with trial site for the full timeframe).
- People who score 8 or higher on the Geriatric Depression Scale (a standard depression screening tool) at the initial screening visit.
- People who have reported certain levels of suicidal thoughts or behaviour in the past 6 months, or who have been hospitalised or treated for suicidal behaviour in the past 5 years before screening.
- People who have surgery planned during the study period that would require general anaesthesia.
- People with severe vision or hearing problems that would prevent them from completing the study's thinking and memory tests accurately.
- Women who are able to become pregnant, or who are currently breastfeeding.
- People who have been taking any nutritional or medicinal supplements within 6 weeks before joining the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If you need support right now
This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.
If you or someone else is in immediate danger, call 000.
- Lifeline — 24/7 crisis support: 13 11 14
- Suicide Call Back Service — 24/7 counselling: 1300 659 467
- 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
- Beyond Blue — 24/7 mental health support: 1300 22 4636
- Emergency: 000
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.
Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Principal Investigator: Fernando Pagan, M.D., Georgetown University
Phone: 757-802-5001
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]; Incidence of abnormal Electrocardiogram (ECG) findings [Safety and Tolerability]); Determination of Jotrol's safe and tolerable dose in plasma [Safety and Tolerability]; Determination of Jotrol's safe and tolerable dose in Cerebral Spinal Fluid (CSF) [Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.